EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails

Laibah Arshad Khan, Bakhtawara Alam, Naresh Kumar Ladhwani, Hamna Abid, Zain Mazhar, Saim Umar Gondal, Jawria Tufail, Ahmed Zia, Syeda Zil E Zehra Naqvi, Muhammad Usama Saeed, Zain Ui Abideen, Vishaka Sahjwani und 4 weitere

American Journal of Nephrology · 2025

DOI: 10.1159/000546265 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift American Journal of Nephrology, 2025. Verfasst von Laibah Arshad Khan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Mississippi Medical Centre, Jackson, Mississippi, USA. Hauptthemen laut MEDLINE: Renal Dialysis, Hyperphosphatemia, Sulfonamides, Isoquinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tenapanor is currently seen as a promising treatment for hyperphosphatemia in haemodialysis patients. Although previous meta-analysis has investigated its efficacy and safety, the potential impact of tenapanor remained a topic of further investigation. This meta-analysis aims to provide an updated and thorough assessment of tenapanor efficacy in reducing serum phosphate levels and its safety in haemodialysis patients, integrating new evidence and refining the analysis of treatment outcomes. Methodology: In this systematic review and meta-analysis, we searched online databases up to August 2024 for studies evaluating the efficacy and safety of tenapanor in haemodialysis patients. Only short-term randomized controlled trials (4 to 8 weeks) comparing tenapanor with placebo were included. The primary outcome was the change in serum phosphate levels from baseline. Safety was assessed based on data regarding drug-related adverse effects (AEs), including diarrhoea and other gastrointestinal AEs.

Results

Among the selected 8 clinical trails with a total of 1001 patients, tenapanor showed a significant reduction in serum phosphate levels from baseline compared to placebo (mean difference [MD] -1.39mg/dl, 95% CI: -1.94,0.84, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisHyperphosphatemiaSulfonamidesIsoquinolinesHumansRandomized Controlled Trials as TopicTreatment OutcomePhosphates

Stichwörter der Autor:innen

Chronic kidney diseaseHemodialysisHyperphosphatemiaPhosphate managementPlacebo-controlled trialRenal dialysisSerum phosphateTenapanor

Substanzen

tenapanorSulfonamidesPhosphatesIsoquinolines

Autor:innen und Institutionen

  • Department of Medicine, University of Mississippi Medical Centre, Jackson, Mississippi, USA.
  • Rehman Medical College, Peshawar, Pakistan, bakhtawar.23a@gmail.com.
  • Civil Hospital, Mīrpur Khās, Pakistan.
  • Services Institute of Medical Sciences, Lahore, Pakistan.
  • Department of Medicine, Faisalabad Medical University, Faisalabad, Pakistan.
  • Alnafees Medical College, Islamabad, Pakistan.

Zitieren

APA

Khan, L. A., Alam, B., Ladhwani, N. K., Abid, H., Mazhar, Z., Gondal, S. U., Tufail, J., Zia, A., Naqvi, S. Z. E. Z., Saeed, M. U., Abideen, Z. U., Sahjwani, V., Lohana, O. K., Kumar, V., Ali, S., & Amjad, Z. (2025). Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails. American Journal of Nephrology. https://doi.org/10.1159/000546265

Vancouver

Khan LA, Alam B, Ladhwani NK, Abid H, Mazhar Z, Gondal SU, et al. Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails. American Journal of Nephrology. 2025. doi:10.1159/000546265

BibTeX
@article{Khan2025,
  author = {Khan, Laibah Arshad and Alam, Bakhtawara and Ladhwani, Naresh Kumar and Abid, Hamna and Mazhar, Zain and Gondal, Saim Umar and Tufail, Jawria and Zia, Ahmed and Naqvi, Syeda Zil E Zehra and Saeed, Muhammad Usama and Abideen, Zain Ui and Sahjwani, Vishaka and Lohana, Om Kumar and Kumar, Varoon and Ali, Saiyad and Amjad, Zainab},
  title = {Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails},
  journal = {American Journal of Nephrology},
  year = {2025},
  doi = {10.1159/000546265}
}
Kostenlos starten →